50 Participants Needed

Speech Processor Programming for Single-Sided Deafness with Cochlear Implant

Recruiting at 1 trial location
LK
JB
Overseen ByJill B Firszt, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

Interaural loudness and pitch mismatch in single-sided deaf cochlear implant (SSD-CI) recipients reduces binaural processing cues and contributes to performance outcomes, specifically speech understanding in noise and localization. The study aims to improve binaural cues through speech processor program modifications that reduce interaural mismatches.

Research Team

JB

Jill B Firszt, PhD

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for adults over 18 with single-sided deafness (SSD) who have normal hearing in one ear and are either experienced users of a Nucleus cochlear implant or will be newly implanted. They must have had postlingual onset of SSD, meaning they became deaf after having learned to speak.

Inclusion Criteria

Implanted with or chosen to be implanted with a Nucleus cochlear implant
I am an adult with hearing loss in one ear.
Postlingual onset of SSD
See 3 more

Exclusion Criteria

Not meeting the inclusion criteria

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

CI speech processor programming to reduce interaural loudness and pitch mismatch

6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Treatment-modifications to CI speech processor program
Trial Overview The study tests modifications to the speech processor program of cochlear implants in individuals with SSD. The goal is to improve binaural cues which help with understanding speech in noisy environments and sound localization by reducing loudness and pitch differences perceived between ears.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
CI speech processor programming

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

Cochlear

Industry Sponsor

Trials
96
Recruited
6,300+
Headquarters
Sydney, Australia

Dig Howitt

Cochlear

Chief Executive Officer since 2018

BE (Hons), MBA

Michael del Prado

Cochlear

Chief Medical Officer since 2022

MD, MSc, FRACP, FAAHMS, FAICD

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security